Literature DB >> 2161323

Progress in vaccine development for prevention of human cytomegalovirus infection.

E Gönczöl1, S Plotkin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2161323     DOI： 10.1007/978-3-642-74980-3_10

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN： 0070-217X            Impact factor:   4.291


× No keyword cloud information.
  4 in total

1.  A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus.

Authors:  B Wagner; B Kropff; H Kalbacher; W Britt; V A Sundqvist; L Ostberg; M Mach
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

2.  Inactivation of human cytomegalovirus by sodium periodate oxidation.

Authors:  F Geoffroy; G Ogier; J Chantepie; G Quash
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

3.  Humoral immune response to human cytomegalovirus DNA polymerase.

Authors:  M P Landini; T Lazzarotto; P F Ertl
Journal:  J Clin Microbiol       Date:  1993-03       Impact factor: 5.948

4.  The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease.

Authors:  M J Reddehase; M Balthesen; M Rapp; S Jonjić; I Pavić; U H Koszinowski
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.